On April 2, 2025, Mr. Fabio Schina, Consul General of Italy in Chongqing, and his entourage visited Olymvax and had in-depth exchanges with the Company’s senior management on the cooperation prospects in the biomedical field.
Mr. Fabio Schina spoke highly of Olymvax’s achievements in the pharmaceutical industry, introduced the current situation of Italy’s biomedical industry, and elaborated on the ongoing medical cooperation between the Chengdu-Chongqing region and Italy. Mr. Fabio Schina stated that there is huge potential for cooperation between Italy and China in the medical and health sector, and welcomed Olymvax to establish long-term cooperative relations with Italian parties to promote the coordinated development of the Chinese and Italian pharmaceutical industries and explore cooperation opportunities in Italy and the European market.
Mr. Fan Shaowen, Chairman and General Manager of Olymvax, extended a warm welcome to the Consul General and his entourage, and introduced the Company’s innovation-driven strategy and internationalization strategy in detail. Mr. Fan Shaowen said that Italy is an important hub of the European pharmaceutical industry, with an advanced medical system and a mature scientific research environment. Olymvax looks forward to establishing cooperative relations with Italian pharmaceutical industry institutions, well-known universities,and renowned technical experts in the future to jointly promote the R&D and commercialization of innovative drugs.
Adhering to the two-way international development strategy of “Bringing In and Going Global”, Olymvax has established solid cooperative relations with Australia and other countries. This meeting laid a solid foundation for the Company to deepen pharmaceutical cooperation with Italy and Europe, marking an important step forward in the Company’s internationalization strategy. In the future, Olymvax will continue to commit to the R&D and production of human vaccines, accelerate the implementation of international cooperation, and provide innovative and high-quality solutions to major global health issues.